Aimee Luck Murphy

VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA.